Compare GSK plc (GSK) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Tapestry, Inc. — how do they compare? GSK plc trades at $50.28 (market cap $102.60B), while Tapestry, Inc. trades at $153.58 (market cap $32.44B). The key difference: GSK plc is far larger — about 3.2× Tapestry, Inc.'s market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| GSK | TPR | |
|---|---|---|
Market Cap | $102.60B | $32.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $164.78 |
52-Week Low | $38.22 | $95.69 |
Enterprise Value | $123.04B | $35.29B |
Dividend Yield | 3.57% | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.
GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.
TPR trades at $153.17, down 7.05% over 24 hours, with a bullish technical signal from moving averages and strong analyst consensus. The company reported Q1 2026 EPS of $1.66, beating expectations of $1.30, and maintains robust profitability with a gross margin of 76.18% and ROE of 55.74%. Recent news highlights AI integration efforts and upcoming Q4 earnings on August 13, 2026.
Outlook is positive driven by earnings beats and brand momentum, but risks include high valuation multiples and debt levels. The consensus price target is $190.33, implying significant upside, supported by 75.61% buy ratings from analysts. Investors should monitor Q2 2026 earnings and debt management for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
